Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $71M (up 81958.1% year over year) with net income of −$35M.
Q3 2025 key financials · XBRL
- Revenue
- $71M
- +81958.1% YoY · +93993.3% QoQ
- Net income
- −$35M
- +54.9% YoY · +65.7% QoQ
- Operating margin
- -56.7%
Source: XBRL data from the Viridian Therapeutics, Inc.\DE (VRDN) Q3 2025 10-Q on SEC EDGAR. USD.
Viridian Therapeutics, Inc.\DE Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Potential failure to meet DRI Purchase and Sale Agreement milestones after October 2025, risking up to $245M in milestone payments
- Updated clinical development risk: FDA may require additional patients beyond 300 in safety databases for veligrotug and VRDN-003, potentially delaying approvals
- Regulatory risk: Post-approval obligations include costly phase 4 trials, REMS programs, and compliance inspections by FDA, EMA, and other authorities
- Market risk: Commercial success dependent on third-party payor reimbursement, pricing, and market acceptance of products if approved
- Financial risk: Cash $490.9M as of September 30, 2025 to fund operations 12+ months; additional capital likely needed, raising dilution and restrictive covenants concerns
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Viridian Therapeutics, Inc.\DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.